论文部分内容阅读
目的对依达拉奉联合奥扎格雷钠治疗急性脑梗死的临床疗效及安全性进行评价。方法108例急性脑梗死患者随机分为2组;治疗组54例,在常规支持疗法基础上采用依达拉奉+奥扎格雷钠治疗;对照组54例,除不使用依达拉奉外,其他同治疗组。结果治疗组有效率为88.9%,明显高于对照组的68.5%,两组比较P<0.05。在用药过程及疗程后复查血尿常规、肝肾功能检查,未发现明显不良反应。结论依达拉奉联合奥扎格雷钠治疗急性脑梗死安全、有效,值得临床推广。
Objective To evaluate the clinical efficacy and safety of edaravone combined with ozagrel sodium in the treatment of acute cerebral infarction. Methods One hundred and eighty patients with acute cerebral infarction were randomly divided into two groups. The treatment group (n = 54) was treated with edaravone and ozagrel sodium on the basis of conventional supportive therapy. In the control group, 54 cases were treated with edaravone, Other with the treatment group. Results The effective rate of the treatment group was 88.9%, significantly higher than that of the control group (68.5%), P <0.05. In the course of medication and after treatment review hematuria, liver and kidney function tests, no significant adverse reactions. Conclusion Edaravone combined with ozagrel sodium in the treatment of acute cerebral infarction is safe and effective and is worthy of clinical promotion.